TY - JOUR
T1 - Renal Neuroendocrine Neoplasms
T2 - A Single-center Experience
AU - McGarrah, Patrick W.
AU - Westin, Gustavo F.M.
AU - Hobday, Timothy J.
AU - Scales, Joseph A.
AU - Ingimarsson, Johann P.
AU - Leibovich, Bradley C.
AU - Halfdanarson, Thorvardur R.
N1 - Publisher Copyright:
© 2019
PY - 2020/8
Y1 - 2020/8
N2 - Renal neuroendocrine neoplasms are rare, with little to no data available on prognosis and treatment outcomes. We present the largest single-institution series of 17 patients, with a median follow-up of 62.8 months. After aggressive resection, the median time to recurrence was 18 months, and the median overall survival was 143 months. Somatostatin analogs provided disease stability in 4 of 9 patients.
AB - Renal neuroendocrine neoplasms are rare, with little to no data available on prognosis and treatment outcomes. We present the largest single-institution series of 17 patients, with a median follow-up of 62.8 months. After aggressive resection, the median time to recurrence was 18 months, and the median overall survival was 143 months. Somatostatin analogs provided disease stability in 4 of 9 patients.
KW - Horseshoe kidney
KW - Kidney carcinoid
KW - Rare cancers
KW - Renal carcinoid
KW - Renal neuroendocrine carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85077311764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077311764&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2019.11.003
DO - 10.1016/j.clgc.2019.11.003
M3 - Article
C2 - 31911122
AN - SCOPUS:85077311764
SN - 1558-7673
VL - 18
SP - e343-e349
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 4
ER -